Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9686102 | 0.72 | ALDH1A1 (0.38) | MEN1ALDH1A1KMT2A | |
| SCHEMBL7037922 | 0.71 | ALDH1A1 (0.36) | MEN1ALDH1A1KMT2A | |
| SCHEMBL7688725 | 0.70 | ALDH1A1 (0.42) | MEN1ALDH1A1KMT2A | |
| SCHEMBL28301147 | 0.69 | CYP1A2 (0.39) | MEN1ALDH1A1KMT2A | |
| SCHEMBL612167 | 0.68 | ALDH1A1 (0.34) | MEN1ALDH1A1KMT2A | |
| SCHEMBL9010837 | 0.68 | ALDH1A1 (0.35) | MEN1ALDH1A1KMT2A | |
| SCHEMBL4404534 | 0.68 | ALDH1A1 (0.34) | MEN1ALDH1A1KMT2A | |
| SCHEMBL94916 | 0.68 | ALDH1A1 (0.34) | MEN1ALDH1A1KMT2A | |
| SCHEMBL16513160 | 0.68 | ALDH1A1 (0.34) | MEN1ALDH1A1KMT2A | |
| SCHEMBL7168417 | 0.68 | ALDH1A1 (0.34) | MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002085904-A1 | SNYTHESIS AND METHODS OF USE OF PURINE ANALOGUES AND DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020156277-A1 | Synthesis and methods of use of purine analogues and derivatives | NEO THERAPEUTICS, INC. | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156277-A1 | Synthesis and methods of use of purine analogues and derivatives | SLC29A1, ATIC, PNP | MEN1 1223/4885ALDH1A1 834/4885KMT2A 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.